The efficacy and tolerance of triple oral DMARD therapy vs. anti-TNF drugs plus methotrexate, was explored.
After 3-month extension to review, regulator says NDA for baricitinib cannot be approved in its current form.
Prospective cohort study examines clinical characteristics and outcomes of S aureus bacteremia in patients with rheumatoid arthritis.
Jonathan Krant, MD, FACP, confronts the issues surrounding biosimilar substitution for biologic treatments.
This week, a phase III trial for investigational drug voclosporin for lupus nephritis treatment was approved, prolonged insomnia may lead to less robust bone formation — causing osteoporosis and bone fractures — and researchers found that women who drink a moderate amount of alcohol daily have a reduced risk of developing systemic lupus erythmatosus.
Study analyzed medical records to determine whether alcohol consumption increases hepatotoxic risk in patients with rheumatoid arthritis being treated with methotrexate.
Investigators conduct a systematic review to evaluate the risks and benefits of biologics as monotherapy or in combination with methotrexate in patients with rheumatoid arthritis who have not responded to previous biologic treatment.
WCO 2017, FDA grants Rituxan Breakthrough Therapy status, and a close-up of pediatric Sjögren's syndrome highlight this week's The Handoff.
FDA gives breakthrough therapy designation to rituxan for treatment of pemphigus vulgaris and is indicated for treating rheumatoid arthritis
Study evaluated hand function and potential influence of functional loss on patients' overall physical functions, health-related quality of life, and psychological status in patients with rheumatoid arthritis and systemic sclerosis.
Janus kinase and signal transducers and activators of transcription inhibitors represent promising treatment targets in RA.
A small study from Romania evaluated whether the presence of osteoarthritis had an effect on the parameters used to evaluate disease activity in patients with early rheumatoid arthritis.
Ultrasonography detects different ankle pathologies in various inflammatory rheumatic diseases.
Study uses registry data from Sweden to evaluate heart failure risk before and after diagnosis of rheumatoid arthritis.
New guidelines for rheumatoid arthritis treatment with DMARDs and money being steered into lupus research highlight this week's The Handoff.
Tocilizumab therapy showed rapid improvement in ocular parameters for uveitis in juvenile idiopathic arthritis patients.
Researchers examined the long-term safety of glucocorticoid use in patients with early rheumatoid arthritis, defined as disease duration <6 months, from the multicenter observational Etude et Suivi des POlyarthrites Indifférenciées Récentes (ESPOIR) cohort.
EULAR has released new recommendations for rheumatoid arthritis management with disease-modifying antirheumatic drugs.
Study examined patients with active rheumatoid arthritis who failed to derive benefit from or were intolerant to TNF-inhibitor therapy.
Analysis finds rapid increase in the risk of non-ischemic heart failure after onset of rheumatoid arthritis.
An observational cohort study of 4961 women with completed pregnancies and a recorded diagnosis of systemic inflammatory conditions.
One in four adults in the U.S. have been diagnosed with arthritis.
A phase 3, double-blind, randomized placebo-controlled study was conducted in 551 patients with active rheumatoid arthritis who received secukinumab, abatacept, or placebo.
Study evaluated breast milk samples from 17 lactating mothers diagnosed with rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis.
Study reviewed information from 1.8 million individuals in England admitted to a hospital with an autoimmune disease.
Connecticut considers rheumatoid arthritis and fibromyalgia for medical marijuana treatment, while Lyme disease-carrying deer ticks continue to invade Michigan. All this and more in this week's edition.
Research comes from meta-analysis of 25 population-based studies on 5 major forms of arthritis.
Cohort study of patients with rheumatoid arthritis who newly initiated tocilizumab or tumor necrosis factor inhibitor therapy using multi-database claims data.
Phase 3 trial in patients taking baricitinib, adalimumab, or placebo in addition to methotrexate background therapy.
Cytomegalovirus Connection With Rheumatoid Arthritis Cardiovascular Disease Risk: An Expert InterviewMarch 01, 2017
Florian Kern, deputy director of research at Brighton and Sussex Medical School in the United Kingdom, discusses his recently published review wherein he and his colleagues make the case that cytomegalovirus is a major driver of cardiovascular disease in patients with rheumatoid arthritis.
Rheumatology Advisor Articles
- Rheumatoid Arthritis Increases Mortality Risk in Staphylococcus aureus Infections
- First Clinical Practice Guidelines for Sjögren's Syndrome Developed
- Antibiotic Resistance Problem Brought Before Congress
- FDA Delays Approval of JAK Inhibitor Baricitinib
- How Effective is RF Denervation for Symptomatic Knee OA?
- Allopurinol Use In Concomitant Gout and Diabetes Lowers Cardiovascular Event Risk
- Measuring Disease Activity in Psoriatic Arthritis
- JAK/STAT Inhibitors: A New Treatment Target for Rheumatoid Arthritis
- Biosimilar Confidence: Physician-Patient Communication Sets the Tone
- VA and DoD Practice Guideline Update: Opioids for Chronic Pain
- Leg Positioning During Lumbar DXA Does Not Impact Trabecular Bone Scores
- Should Trabecular Bone Score Be Used to Predict Fragility Fracture Risk in T1D?
- DXA for Pediatric Bone Age Assessment Yields Similar Results vs Traditional Radiography
- Remote Osteoporosis Specialist Mentoring Program Improves Physician Self-Confidence
- Increased Costs Associated With Specialists Providing Primary Care